Fig. 2From: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label studyGlobal Impression of Change following 3 months treatment with opicapone 50 mg (LOCF) (a) investigator rated (CGI-C, n = 477); (b) self-rated by the patient (PGI-C, n = 393)Back to article page